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Br J Pharmacol. 2019;1–17.Background and Purpose: Calcification of heart valves is a frequent pathological
finding in chronic kidney disease and in elderly patients. Hydrogen sulfide (H2S)
may exert anti‐calcific actions. Here we investigated H2S as an inhibitor of valvular
calcification and to identify its targets in the pathogenesis.
Experimental Approach: Effects of H2S on osteoblastic transdifferentiation of val-
vular interstitial cells (VIC) isolated from samples of human aortic valves were studied
using immunohistochemistry and western blots. We also assessed H2S on valvular
calcification in apolipoprotein E‐deficient (ApoE−/−) mice.
Key Results: In human VIC, H2S from donor compounds (NaSH, Na2S, GYY4137,
AP67, and AP72) inhibited mineralization/osteoblastic transdifferentiation, dose‐
dependently in response to phosphate. Accumulation of calcium in the extracellular
matrix and expression of osteocalcin and alkaline phosphatase was also inhibited.
RUNX2 was not translocated to the nucleus and phosphate uptake was decreased.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 SIKURA ET AL.BJPPyrophosphate generation was increased via up‐regulating ENPP2 and ANK1. Lower-
ing endogenous production of H2S by concomitant silencing of cystathionine γ‐lyase
(CSE) and cystathionine β‐synthase (CBS) favoured VIC calcification. analysis of
human specimens revealed higher Expression of CSE in aorta stenosis valves with
calcification (AS) was higher than in valves of aortic insufficiency (AI). In contrast,
tissue H2S generation was lower in AS valves compared to AI valves. Valvular calcifi-
cation in ApoE−/− mice on a high‐fat diet was inhibited by H2S.
Conclusions and Implications: The endogenous CSE‐CBS/H2S system exerts anti‐
calcification effects in heart valves providing a novel therapeutic approach to prevent
hardening of valves.What is already known
• Hydrogen sulfide (H2S) inhibits osteoblastic
transformation of vascular smooth muscle cells.
What this study adds
• CSE‐ and CBS‐derived H2S and H2S‐releasing donors
inhibit mineralization of aortic valves.
• Anti‐calcification occurs via inhibiting phosphate uptake,
preventing nuclear translocation of RUNX2, and
increasing pyrophosphate levels.
What is the clinical significance
• H2S‐releasing donors and CSE/CBS‐derived H2S have
therapeutic potential in calcific aortic valve disease.1 | INTRODUCTION
In the developed countries, calcific aortic valve disease (CAVD), an
actively regulated disease process, is the most common valvular heart
disease with high morbidity and mortality (Yutzey et al., 2014).
Numerous studies show that CAVD is accompanied by calcification,
lipid accumulation, and inflammation resulting in heterogeneous
lesions within the heart valvular tissue. The ratio of the calcified and
non‐calcified regions could guide in distinguishing the state of calcifi-
cation (Chester, 2011; Lusis, Mar, & Pajukanta, 2004; Mohler, 2004;
Mohler et al., 2001; Speer & Giachelli, 2004).
Cardiovascular calcification is a complex, chronic disease of the
major and medium‐sized arteries including those in aortic valves. Such
calcification is involved in the increased risk of cardiovascular morbid-
ity and mortality. Pathologically, it is well known that its progression is
much more pronounced in patients with diabetes and chronic kidney
disease (CKD; Davignon & Ganz, 2004; Libby, Ridker, & Maseri,
2002; Rajamannan et al., 2011; Stocker & Keaney, 2004).
Hydrogen sulfide (H2S) is the third endogenous gasotransmitter,
along with NO and carbon monoxide (Wang, 2002). Previously, our
laboratory demonstrated that NaSH (a H2S donor compound)
significantly inhibits the mineralization of vascular smooth muscle cells
(Zavaczki et al., 2011). Jiang,Wu, Li, Geng, & Tang (2005) and nowmany
groups have shown cystathionine γ‐lyase (CSE) in cardiac tissue and it
is important for normal heart function (Chen, Xin, & Zhu, 2007). They
demonstrated that disturbance of H2S production contributed to the
development of heart diseases as manifested by lower levels of H2S in
plasma, in patients with coronary heart disease (Jiang et al 2005; Shen,
Shen, Luo, Guo, & Zhu, 2015). Furthermore, Abe and Kimura (1996)
presented for the first time that endogenous H2S production by
cystathionine β‐synthase (CBS) contributed to normal brain function.
Kang, Neill, and Xian (2017) synthesized a new generation, slow
release, H2S donor compound (GYY4137) from Lawesson's reagent
and morpholine. Protonation of GYY4137 resulted in more stable
H2S‐releasing compounds such as AP67 and AP72. AP72 has an excel-
lent water solubility and a very slow generation of H2S, compared to
the fast H2S‐releasing donors such as NaSH and Na2S (Chitnis et al.,
2013; Kang et al., 2017; Nagy et al., 2014).In calcified valves, the valvular interstitial cells (VIC)
transdifferentiate into osteoblast‐like cells, identified by up‐regulation
of alkaline phosphatase (ALP) activity, and increased levels of
osteocalcin expression at later stages (Rajamannan et al., 2003). One
of the most potent, recognized inducers of vascular calcification is
raised levels of plasma phosphate, in CKD patients (Becs et al., 2016).
The increase in its intracellular level promotes nuclear translocation of
the osteogenic transcription factor RUNX2 resulting in transition of
cells towards an osteoblast phenotype (Ducy, Zhang, Geoffroy, Ridall,
& Karsenty, 1997). Phosphate uptake occurs via phosphate carriers
Pit1 and Pit2 (Crouthamel et al., 2013; X. Li, Yang, & Giachelli, 2006).
Pyrophosphate (PPi) is a key regulator of tissue calcification via
inhibition of mineralization by binding to nascent hydroxyapatite
crystals. Ectonucleotide pyrophosphatase/PDE‐2 (ENPP2) is a cell
membrane glycoprotein that generates PPi via cleaving ATP. Ankyrin
G1 (ANK1) is a transmembrane protein which has a critical role in
the regulation of pyrophosphate levels. The main function of ANK1
is transporting intracellular PPi into the extracellular space (Jansen
et al., 2012; Mitton‐Fitzgerald, Gohr, Bettendorf, & Rosenthal, 2016).
SIKURA ET AL. 3BJPThe purpose of this study was to explore the effects of H2S donors
(NaSH, Na2S, GYY4137, AP67, or AP72) on the development of calci-
fication in human VIC and ApoE−/− mice fed with atherogenic diet and
to investigate its underlying mechanism with regard to the develop-
ment of atherosclerosis and mineralization. Our study identifies a
novel potential treatment for preventing and/or reversing valvular
calcification.2 | METHODS
2.1 | Human tissue samples and cell isolation
Human aortic valve leaflets were obtained from patients undergoing
valve replacement for stenosis with calcification (AS; N = 52) and
patients who had severe insufficiency without calcification (AI; N = 28).
The specimens were collected from January 2015 to December 2017
(80 patients; Regional Research Ethical Committee, Project No.:
61538‐2/2017/EKU and 4699‐2016). VIC were isolated from human
heart valves using collagenase (600 U·ml−1; Worthington Biochemical
Corp.). Cells isolated from donors were employed at passages 2 to 4.
All experiments were performed on cells derived from five different
donors.2.2 | Animals
All animal care and experimental procedures complied with the
guidelines from Directive 2010/63/EU of the European Parliament
on the protection of animals used for scientific purposes, and were
approved by the Scientific and Research Ethics Committee of the
Scientific Council of Health of the Hungarian Government under
the registration number of DE MÁB/157‐5/2010. Animal studies
are reported in compliance with the ARRIVE guidelines (Kilkenny
et al., 2010) and with the recommendations made by the British
Journal of Pharmacology.
C57BL/6 ApoE−/− mice (The Jackson Laboratory; B6.129P2
Apoetm1Unc/J; RRID:IMSR_JAX:002052) were maintained at the
University of Debrecen under specific pathogen‐free conditions in
accordance with the guidelines from the Institutional Ethical Commit-
tee. Mice were randomly divided into three groups. Non‐high fat diet
group (N = 5) received a standard chow diet. To induce aortic valve
calcification, mice were given an atherogenic diet (15% fat, 1.25%
cholesterol, ssniff Spezialdiäten GmbH, Soest, Germany) from the
age of 8 weeks. The detailed composition of the atherogenic food
(high‐fat diet) was as follows: crude nutrients (%): crude protein
19%, crude fat 15.2%, crude fibre 3.4%, crude ash 6.3%, starch
25.6%, sugar 11.2%; additives (per kg): vitamin A 15,000 IU, vitamin
D3 1,000 IU, vitamin E 110 mg, vitamin K3 5 mg, vitamin C 0 mg,
copper 13 mg. While on the atherogenic diet, mice were injected
intraperitoneally with AP72 (266‐μmol·kg−1; N = 5) or vehicle (saline;
N = 9) on every other day as previously described (Potor et al.,
2018). Aortas were collected after 8 weeks of treatment. All micewere killed by a predictable and controllable administering slow‐fill
compressed CO2 asphyxiation.2.3 | Induction of calcification, calcium
measurement, and Alizarin Red S staining
The VIC were cultured in a calcification medium (2.5‐mmol·L−1
inorganic phosphate and 1.8‐mmol·L−1 calcium–chloride) with or
without phenol red for 5 days. Calcium content of the supernatants
was determined by QuantiChrome Calcium Assay Kit (Gentaur),
normalized to protein content, and expressed as μg·mg−1 protein.
Alizarin Red S staining was used to visualize the calcium deposition.
Plates were fixed with 3.7% formaldehyde for 10 min followed by
staining with a 2% solution of Alizarin Red S. Pictures from the stained
cells were taken with a light microscope (×10 magnification; Leica
DMIL LED microscope).2.4 | Quantification of osteocalcin
ELISA kit was used (Bender MedSystem) for the quantification of the
osteocalcin from EDTA‐solubilized extracellular matrix.2.5 | ALP staining
To visualize ALP activity, cells were cultured in 24‐well plates and
fixed in citrate–acetone solution (2:3) followed by staining with
Naphtanol AS‐MX Fast Violet B solution (Sigma). Light microscope
pictures were taken from the different treatments (Leica DMIL LED
microscope, Leica DMC4500 camera with Leica application suite LAS
Software 4.9.0).2.6 | Cell viability assay
Cells were cultured on 0.2% collagen type I coated coverslip.
NUCLEAR‐ID® Blue/Red cell viability reagent was added to the cells
at dilution 1:1,000 for 30 min at 37°C. Then, the cells were fixed with
Fluorescent Mounting Medium (Dako) on Superfrost Ultra Plus
Microscope Slide (Thermo Scientific). Images were obtained with an
immunofluorescence microscope (Leica DM2500 microscope, Leica
DFC480 camera).2.7 | Immunofluorescence staining
The antibody‐based procedures used in this study comply with the
recommendations made by the British Journal of Pharmacology. Cells
were cultured on the coverslip and treated with or without calcifica-
tion medium, with or without phenol red, supplemented with
20‐μmol·L−1 AP72 for 24 hr and for 2 days. After treatment, the cells
were fixed with 3.7% formaldehyde for 15 min. After fixation, cells
were blocked with 10% goat serum for 1 hr at room temperature.
Rabbit polyclonal anti‐human RUNX2 (Proteintech Group Cat#
20700‐1‐AP, RRID:AB_2722783) was used (dilution 1:600) as a
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body labelled with goat anti‐rabbit Alexa 488 (Molecular Probes
Cat# A‐11070, RRID:AB_142134) fluorophore at dilution 1:500 for
1 hr in dark at room temperature. Hoechst was used to stain nuclei.
Multicolor STED imaging was acquired with STED (stimulated
emission depletion) Leica TCS SP8 gated STED‐CW nanoscopy (Leica
Microsystem Mannheim, Germany). Gated STED images were
deconvolved using Huygens Professional (Scientific Volume Imaging
B.V., Hilversum, Netherlands) software.2.8 | Nuclear and cytoplasmic protein extraction
Cells were cultured in growth medium and treated with or without
calcification medium supplemented with 20‐μmol·L−1 AP72. After
treatment, cells were harvested with cell scraper and collected into a
centrifuge tube. Pellets were washed twice with PBS and then ice‐cold
1× cytoplasmic lysis buffer (20‐mmol·L−1 Tris–HCl pH 8.0, 100‐
mmol·L−1 NaCl, 300‐mmol·L−1 sucrose, 3‐mmol·L−1 MgCl2, protease
inhibitor cocktail) was added to the pellets. Cell suspensions were
incubated on ice for 15 min. After centrifugation, the supernatants
were collected (contains cytoplasmic proteins); the pellets were
washed with PBS and resuspended in ice‐cold nuclear extraction
buffer (20‐mmol·L−1 Tris–HCl pH 8.0, 300‐mmol·L−1 NaCl, 2‐mmol·L−1
EDTA pH 8.0, protease inhibitor cocktail). After that, the samples were
passed five times through a 27 gauge needle, for the extraction of the
nuclear proteins followed by centrifugation at 8,000× g, 4°C for
20 min. The supernatant contains the nuclear fraction. The protein
concentration of the samples was determined by the BCA Protein
Detection Kit (Amersham).2.9 | Western blot
To show RUNX2 translocation into the nucleus, we separated the
nuclei and cytoplasm fractions with the nuclear extraction kit. After
that, nucleus and cytoplasm lysates were separated by electrophoresis
with 10% SDS‐PAGE. After blotting, the membrane was incubated
with rabbit anti‐human RUNX2 (Cbfa‐1) antibody at 1:600 dilution
(Proteintech Group Cat# 20700‐1‐AP, RRID:AB_2722783) for over-
night, followed by HRP‐labelled anti‐rabbit IgG antibody incubation
for 1 hr at room temperature. The membranes were reprobed with
Lamin B1 (Proteintech Group Cat# 12987‐1‐AP, RRID:AB_2136290)
and also GAPDH (Novus Cat# NB300‐221, RRID:AB_10077627).
Briefly, to evaluate Pit1, Pit2, CSE, and CBS protein expressions from
valve tissues, and from the cell, the lysates were electrophoresed with
10% SDS‐PAGE. Western blotting was performed with the following
primary antibodies: rabbit anti‐human Pit1 at dilution 1:500 (Abcam
Cat# ab24756, RRID:AB_448292), rabbit anti‐human Pit2 at 1:500
dilution (Proteintech Group Cat# 12820‐1‐AP, RRID:AB_2191004),
rabbit anti‐human CSE at dilution 1: 600 (Proteintech Group Cat#
12217‐1‐AP, RRID:AB_2087497), rabbit anti‐human CBS at dilution
1:600 (Proteintech Group Cat# 14787‐1‐AP, RRID:AB_2070970),
anti‐human RUNX2 at dilution 1:500 (Proteintech Group Cat#20700‐1‐AP, RRID:AB_2722783), rabbit anti‐human ENPP2 at
dilution 1:500 (Thermo Fisher Scientific Cat# PA5‐12478, RRID:
AB_2231274), and mouse anti‐human Ankyrin G1 antibody at dilution
1:500 (Innovative Research Cat# 33‐8800, RRID:AB_87179). Next,
HRP‐labelled anti‐rabbit IgG antibody was used as a secondary anti-
body. Complexes of antigen–antibody were visualized with a HRP
chemiluminescence detection system (Amersham Biosciences). After
detection, membranes were stripped and reprobed for GAPDH.
Human CSE recombinant protein (MyBiosource, MBS144930) was
used as a control for CSE western blot.2.10 | Quantitative real‐time PCR
VIC were cultured in growth media or calcification media supple-
mented with 20‐μmol·L−1 AP72. After 5 days, cells were harvested.
Total RNA was isolated using RNAzol STAT‐60 according to the man-
ufacturer's instructions (TEL‐TEST Inc., Friendswood, TX, USA). RNA
concentration was measured with NanoDropTM 2000c spectropho-
tometer (Thermo Scientific Inc., Waltham, MA, USA). Subsequently,
cDNA synthesis was performed using a high‐capacity cDNA kit
(Applied Biosystems, Foster City, CA, USA). We used real‐time PCR
technique for quantification of mRNA levels of ENPP2 and ANK1
(Thermo Fisher Scientific Inc.) and GAPDH (Thermo Fisher Scientific
Inc.). TaqMan Universal PCR Master Mix was purchased from Applied
Biosystems. Finally, we performed TaqMan quantitative PCR (40 cycles
at 95°C for 15 s and 60°C for 1 min) on 96‐well plates with the Bio‐
Rad CFX96 (Bio‐Rad Laboratories Inc., Hercules, California, USA)
detection system. Results were expressed as mRNA expression
normalized to GAPDH.2.11 | Intracellular phosphate uptake measurement
The VIC were cultured on 12‐well plates exposed to calcification
medium, with or without of phenol red using DMEM supplemented
with/without AP72 (20 μmol·L−1) for 5 days. Cells were lysed with
0.5% NP40 and 1% Triton‐X100. Whole cell lysate centrifuged at
12,000× g for 15 min at 4°C. The supernatant was measured by
QuantiChrom quantitative colorimetric phosphate assay kit (BioAssays
System) on 96‐well plates at 650 nm. Phosphate uptake was normal-
ized to the protein content of the cells.2.12 | Pyrophosphate assay
VIC were cultured in phenol red‐free growth medium (DMEM; Sigma)
or calcification medium and supplemented with AP72 (20 μmol·L−1).
Heart valve tissues (AS N = 3; AI N = 3) and cells were lysed with
EDTA free detergent. Inorganic pyrophosphate (PPi) was measured
in the extracellular fluid of the VIC using PPiLight™ inorganic pyro-
phosphate assay (Lonza; LT‐07‐610). The continuous kinetic assay
was employed according to the manufacturer's instruction. The lumi-
nescence was monitored for 2 hr using Synergy™ HTX Multi‐Mode
Microplate Reader from BioTek Instruments (USA) with 0.1‐s
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the protein content of the cells.2.13 | Determination of sulfide level from AS and AI
valve tissues with zinc precipitation assay
Sulfide levels were measured with the zinc precipitation method
developed by Gilboa‐Garber (1971) and improved by Ang,
Konigstorfer, Giles, and Bhatia (2012). The human valves were pulver-
ized under liquid N2. Next, the samples were taken up in PBS (pH 7.4),
followed by sonication. After that, the sample was centrifuged at
12,000× g for 15 min, and the lipid‐free, clear supernatant was col-
lected; 200‐μl sample was mixed with 350 μl 1% zinc acetate and
50 μl 1.5‐mol·L−1 sodium hydroxide and incubated for 60 min on a
shaker. The incubation step was followed by centrifugation at
2,000× g for 5 min to pellet the generated zinc sulfide. The superna-
tant was then removed, and the pellet was washed with 1 ml of dis-
tilled water by vortexing extensively, followed by centrifugation at
2,000× g for 5 min. The supernatant was then aspirated off, and the
pellet reconstituted with 160 μl of distilled water and mixed with
40 μl of pre‐mixed dye (20 μl of 20‐mmol·L−1 dimethyl‐p‐
phenylenediamine dihydrochloride in 7.2‐mol·L−1 hydrochloric acid
[HCl] and 20 μl of 30 mmol·L−1 iron [III] chloride [FeCl3] in 1.2‐mol·L
−1 HCl). After 10 min, the absorbance of the generated methylene blue
(MB) was measured with a spectrophotometer at 667 nm. During the
reaction 1‐mol·L−1 MB is formed from 1‐mol·L−1 sulfide. Thus, the
concentration of sulfide is determined using the extinction coefficient
(30 200 M−1 cm−1) of MB. Samples were normalized for protein con-
centration. Results are presented as μmol·L−1 H2S generated mg
−1
protein at 60 min.2.14 | CSE and CBS double gene silencing
CSE and CBS genes were silenced, using appropriate siRNAs (Ambion,
4392420; s3710). Briefly, the VIC were cultured on 12‐well plates in
antibiotic‐free medium (DMEM, Sigma). At about 70% of confluence,
cells were transfected with siRNA against CSE and CBS (Ambion,
4390824; s289). Transfection occurred for 4 hr in minimal serum‐
content medium (Opti‐MEM; Gibco). At the end of transfection, 30%
FBS containing antibiotic‐free DMEM was added. Next day, cells were
washed and treated with AP72 every second day until 5 days. The
sequences of the siRNAs were inserted in Data S1.2.15 | Pharmacological inhibition of CSE and CBS
VIC were cultured in 12‐well plates in growth medium or
calcification medium. Inhibition of CSE, CBS, and 3‐mercaptopyruvate
sulfurtransferase (3‐MST) were carried out with the relevant inhibi-
tors, alone or in combination: DL propargylglycine (PPG), amino‐
oxyacetic acid (AOAA), or α‐ketoglutaric acid (KGA), AOAA + PPG,
AOAA + KGA, and PPG + KGA (each inhibitor at 20 μmol·L−1).2.16 | Double immunostaining of smooth muscle
actin, CSE, and ALP
Fresh valve tissue (AI and AS) samples were fixed in 10% neutral buff-
ered formalin for 2 days and embedded in paraffin wax. Sections
(3‐μm) of tissues were deparaffinized, mounted on slides and stained
for ALP‐CSE or α smooth muscle actin (α‐SMA; Santa Cruz Biotech-
nology Cat# sc‐32251, RRID:AB_262054)‐CSE. In case of the calcified
sample, the tissue was decalcified. Double immunostaining was
performed sequentially with the EnVision FLEX/HRP system. Antibod-
ies were used at a dilution of 1:1,000 in each case. In addition to DAB
(brown colour), chromogen VIP was used to highlight the second
immunohistochemical reaction in a different colour (dark violet). For
double staining experiments, methyl‐green counterstaining was
performed.2.17 | Immunohistochemistry from mouse heart
valves
Briefly, tissues were fixed in formaldehyde for 1 day followed by Tris
buffer and embedded in paraffin wax. Subsequently, slides were
deparaffinized in xylene and then rehydrated. For immunohistochem-
istry, slides were subjected to the peroxidase‐blocking reagent. Sam-
ples were incubated with the following primary antibodies: anti‐CSE
antibody at dilution 1:1,000 (Proteintech Group Cat# 12217‐1‐AP,
RRID:AB_2087497) and anti‐SMA antibody at a dilution of 1:1,000
(Santa Cruz Biotechnology Cat# sc‐32251, RRID:AB_262054). Anti-
body binding was visualized by the Super Sensitive™ One Step
Polymer‐HRP IHC Detection System. Liquid DAB chromogen (BG‐
QD630‐XAKm BioGenex) was added for samples. The intensity and
distribution of antibodies expression were assessed by light micros-
copy (Leica DM2500 microscope, DFC 420 camera, and Leica Applica-
tion Suite V3 software, Wetzlar, Germany).2.18 | LDH cytotoxicity assay
The cytotoxicity of the treatments was assessed by Pierce LDH Cyto-
toxicity Assay Kit (Thermo Scientific) according to the manufacturer's
instructions.2.19 | Data and statistical analysis
Data were analysed by GraphPad Prism 5.02 software (GraphPad
Software Inc., 7825 Fay Avenue, Suite 230 La Jolla, CA 92037;
RRID:SCR_002798). All data are expressed as mean ± SEM. If data
groups passed the normality test and equal variance test, we per-
formed Student's t test or one way ANOVA followed by Bonferroni
post hoc tests as indicated in figure legends. P < .05 was considered
significant.
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All chemicals were analytical reagent grade or higher and
obtained from Sigma‐Aldrich (St Louis, MO, USA). The sulfide
donor molecules used in this work—GYY4137 (P‐(4‐methoxy-
phenyl)‐P‐4‐morpholinylphosphinodithioic acid morpholine salt),
AP67 (4‐methoxyphenyl)(pyrrolidin‐1‐yl)phosphinodithioc acid), and
AP72 (4‐methoxyphenyl)(piperidin‐1‐yl)phosphinodithioc acid)—were
synthesized in‐house (Kulkarni‐Chitnis et al., 2015; L. Li et al.,
2008; Whiteman et al., 2015). Sulfide stock solutions were prepared
fresh daily in water.2.21 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro
et al., 2017; Alexander, Kelly et al., 2017)3 | RESULTS
3.1 | H2S prevents calcification of VIC
We compared the potential of different H2S donors for inhibiting cal-
cification of VIC isolated from human aortic valves. Cells were main-
tained in calcification medium containing 2.5‐mmol·L−1 inorganic
phosphate and 1.8‐mmol·L−1 calcium–chloride. VIC were treated with
H2S from two sources. One source of H2S was the simple sulfide salts
NaSH and Na2S that instantaneously generates H2S via pH‐dependent
salt dissociation and the other was the novel slow‐release sulfide
donors (AP67 and AP72) and the more commonly used donor
GYY4137 (synthesized in‐house). As expected, the transition of VIC
into osteoblasts occurred in the calcifying environment, which is
reflected by the calcium accumulation in the extracellular matrix
(Figure 1) and the increased expression of osteocalcin and ALP
(Figure 2). Importantly, all H2S donors decreased calcium deposition
in a dose‐dependent fashion (Figure 1). NaSH reached the maximum
inhibition at 150 μmol·L−1 (Figure 1a), Na2S and GYY4137 attenuated
calcification at 100 μmol·L−1 (Figure 1b,c), while AP67 suppressed cal-
cification at 50 μmol·L−1 (Figure 1d), compared to calcification medium
without H2S supplementation. Among the H2S donors, AP72 fully
prevented calcium deposition in the extracellular matrix of VIC at
20 μmol·L−1 concentration (Figure 1e,f). Furthermore, osteocalcin
accumulation and expression of ALP in VIC along with calcium deposi-
tion were also prevented by AP72 (20 μmol·L−1; Figure S3A–C).
Similarly, other fast (NaSH and Na2S) and slow (GYY4137 and AP67)
sulfide‐releasing compounds significantly attenuated the secretion of
osteocalcin (Figure S1A). ALP and Alizarin Red S staining showed
pronounced osteoblastic transformation of VIC in the calcific environ-
ment, and this effect was prevented by AP72 (Figure S3C,D). Asdemonstrated in Figure S3E, AP72 did not exhibit any cytotoxic
effects on VIC at the applied dose. We observed a “U” shape curve
in the inhibition of mineralization. The use of H2S donors at concen-
trations in excess of that stated above resulted in a concentration‐
dependent decline in protection. From these studies, we then selected
the most effective H2S donor (AP72) for further investigation to
explore the mechanism by which H2S regulates the calcification
processes.
As phenol is known to capture H2S (Huang, Zhang, Zhou, Tao, &
Fan, 2017), we tested if AP72 affects calcification at lower concentra-
tions in phenol red‐free medium, compared to calcification medium
with phenol red. Without phenol red, AP72 significantly inhibited
calcification of VIC at concentration of 2.5 nmol·L−1 to 5 μmol·L−1
(Figure S1B). Accordingly, osteocalcin accumulation was prevented,
and phosphate uptake was also decreased by AP72 in phenol red‐free
condition (Figure 2a,b). ALP and Alizarin Red S staining demonstrated
the inhibitory effect of AP72 at a concentration of 2 μmol·L−1
(Figure 2d,e). As shown in Figure S3, in phenol red‐containing medium,
AP72 exhibited inhibitory effect on calcification in VIC at one‐order
magnitude higher concentration. There was no cytotoxicity in the
VIC cultures due to the sulfide donor compounds, at the most effec-
tive concentrations (Figure S1C).3.2 | AP72 inhibits the phosphate‐induced nuclear
translocation of RUNX2
RUNX2 is a key transcription factor associated with an early osteo-
blastic differentiation of vascular smooth muscle cells and VIC. We
therefore assessed the effects of AP72 treatment on the localization
of RUNX2 in VIC cultured in calcification medium. Immunofluores-
cence staining indicated that RUNX2 was located in the cytoplasm
of VIC cultured in growth medium (control medium; Figure 3a; upper
panels). Phosphate exposure of VIC triggered the translocation of
RUNX2 from the cytoplasm to the nucleus (Figure 3a; middle panels).
As demonstrated in Figure 3a (lower panel), AP72 prevented the
appearance of RUNX2 in the nucleus of VIC maintained in calcification
medium. To support our immunofluorescence observation, cytoplas-
mic and nuclear fractions of VIC were examined for RUNX2 using
western blot analysis. We found that RUNX2 appeared in the nucleus
in response to calcification medium (Figure 3b; left panel), while its
level was decreased in the cytoplasmic fraction (Figure 3b; right panel).
Importantly, AP72 treatment prevented the translocation of RUNX2
into the nucleus of VIC exposed to phosphate (Figure 3b).
Next, we examined the nuclear location of the RUNX2 in VIC
derived from human valves with visible calcification (AS) and without
calcification (AI). Confocal microscopy and western blot analysis
showed that RUNX2 was mainly located in the nucleus of VIC derived
from AS human valve tissue, whereas RUNX2 was detected in the
cytoplasm of VIC derived from AI tissue (Figure 3c,d). Importantly,
exposure of cells to 200 μmol·L−1 of AP72 did not restrain the
nuclear translocation of RUNX2 from the cytoplasm to the nucleus
(Figure S4).
FIGURE 1 H2S donors dose‐dependently
inhibit the calcification of VIC. Calcium
contents of VIC in growth medium or
calcification medium are shown, after 5 days
treatment with (a) NaSH, (b) Na2S, (c)
GYY4137, (d) AP67 (10–200 μmol·L−1), or
with (e) AP72 (5–200 μmol·L−1). (f) Alizarin
Red S staining of VIC. Data shown are
means ± SEM of five independent
experiments. *P < .05, significantly different as
indicated
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PPi is a well‐known anti‐calcification molecule which is regulated by
ENPP2 and ANK1. Therefore, we tested the effects of H2S on PPi pro-
duction, through regulating the expression of ENPP2 and ANK1 in
VIC. As shown in Figure 4a, expression of ENPP2 was decreased in
VIC cultured in calcification medium as compared to control. Treat-
ment of cells with AP72 abolished such an effect. ENPP expression
was significantly elevated above the level observed in control cells
(Figure 4a). Furthermore, the level of ANK1 protein in VIC maintained
under calcifying conditions did not change compared to cells grown in
growth medium. In contrast, AP72 induced ANK1 expression at both
mRNA and protein levels in VIC (Figure 4b). Accordingly, the amount
of PPi generated was decreased in cells grown under calcifying condi-
tions (Figure 4c). In the presence of AP72, PPi generation increased
significantly in VIC, when compared with cells cultured in both controlgrowth medium and calcification medium without any treatment
(Figure 4c). We also tested GYY4137 and AP67 for their effects on
the PPi levels in VIC. These donors enhanced the PPi level less effec-
tively than AP72 (Figure 4c). The fast sulfide‐releasing molecules
(NaSH and Na2S) were able to enhance the PPi level only to the base-
line (Figure S5). Moreover, our measurements in human heart valve
tissue samples indicated significantly lower ENPP2 protein levels and
lower PPi content in AS valve specimens than those in samples from
AI valves (Figure 4d,e).3.4 | Attenuated CSE and CBS expression promotes
VIC calcification
To investigate potential anti‐calcification effects of endogenously
produced H2S we first silenced CSE production in VIC using siRNA.
FIGURE 2 Phenol red impairs anti‐calcification effect of H2S.
Cultured VIC in (a) phenol red‐containing DMEM (Sigma) or (b)
phenol red‐free media were supplemented with AP72 (2 μmol·L−1;
20 μmol·L−1) for 5 days, and calcium content of the cells was
measured and normalized to protein content of the cells. Alizarin Red
S staining represents the microscopic image of calcium deposition of
extracellular matrix. Data shown are means ± SEM of five independent
experiments. *P < .05, significantly different as indicated
8 SIKURA ET AL.BJPWe found that CSE silencing (Figure 5a; right panel) did not signifi-
cantly enhance the calcium accumulation under calcifying conditions
(Figure 5a; left panel). Intriguingly, we observed that CSE silencingincreased the expression of CBS, which is another pyridoxal
5′‐phosphate (PLP or vitamin B6) dependent transsulfuration enzyme
involved in endogenous sulfide production (Figure 5b). Thus, we
silenced both CSE and CBS to test whether calcium deposition in
extracellular matrix was affected. We observed an increase in mineral-
ization after CSE and CBS were concomitantly silenced in VIC
(Figure 5c) suggesting that transsulfuration pathways are likely to con-
trol calcification. Next, we performed experiments with pharmacolog-
ical inhibitors of CSE (PPG) together with CBS (AOAA), in VIC under
calcifying conditions. We found that pharmacological inhibition of
CSE with CBS increased the amount of extracellular calcium deposi-
tion (Figure 5d). Furthermore, we tested all three synthetic inhibitors
for CSE (PPG), CBS (AOAA), and 3‐MST (KGA) alone or in combina-
tion. Calcium depositions of CSE/CBS double silenced VIC shown
inhibition of CSE and CBS altered calcification in VIC (Figure S6A).
Furthermore, AOAA + PPG; AOAA + KGA, and PPG + KGA pharma-
cological inhibitors significantly reduced the H2S production in VIC
(Figure S6B). To our surprise, nuclear translocation of RUNX2 was
not influenced by double silencing of CSE and CBS in calcification
medium (Figure S8). Furthermore, we monitored the progression of
calcification in extracellular matrix on the first and third days. On
the first day, we did not find significant alteration in the calcium
content of VIC maintained in calcifying condition compared to
control. In contrast, we observed a significantly increased extracellu-
lar calcium content in VIC silenced with CSE/CBS siRNA (Figure 5e).
Mineralization was more robust in the double silenced VIC by day
three (Figure 5e). As shown in Figure S7B, production of H2S was
lowered in calcifying conditions, compared to cells cultured in
growth media and that was further decreased by double silencing
for CSE and CBS. Finally, we examined the expression of 3‐MST in
VIC treated with CSE/CBS siRNA. We found that siRNA specific to
CSE and CBS decreased 3‐MST protein level in VIC (Figure S7C).
Western blots of CSE and CBS of double silenced cells are shown in
Figure S8.3.5 | Hydrogen sulfide inhibits phosphate
uptake through affecting the functions of phosphate
channels
As cellular phosphate uptake is a key event in the mineralization pro-
cess, we therefore next measured intracellular phosphate levels in VIC
and observed a significant elevation in cells cultured in calcification
medium, compared to cells kept in control medium (Figure 6a). Expo-
sure of VIC to AP72 diminished this increase in phosphate content
to the level observed in control cells (Figure 6a). In order to explain
the inhibition of phosphate uptake, we measured the expression of
phosphate channels (Pit1 and Pit2) in VIC maintained in calcification
medium, with or without AP72. We found that AP72 did not affect
the expression of Pit1 and Pit2 channels (Figure 6b,c). Therefore, we
hypothesize that sulfide‐induced post‐translational modification of
these channels might affect phosphate uptake. Measurements to
support or disprove this hypothesis are underway.
FIGURE 3 AP72 prevents nuclear
translocation of RUNX2. VIC grown on
coverslips were exposed to growth medium or
calcification medium alone or supplemented
with AP72 (20 μmol·L−1) for 2 days. (a) Cells
were stained for DNA (Hoechst 33258, blue),
RUNX2 (green, Alexa Flour 488), and F‐actin
(cytoskeleton, red, iFluor 647). Images are
obtained employing an immunofluorescence‐
confocal STED nanoscope. (b) RUNX2
expression in cytoplasmic and nuclear fraction
of VIC. The band intensities are normalized for
Lamin B1 in case of nuclear extracts and for
GAPDH in case of cytoplasm extracts. (c)
RUNX2 localization in AI‐ and AS‐derived VIC
samples. Images are obtained employing an
immunofluorescence‐confocal STED
nanoscope. (d) Protein levels of RUNX2 in AI
and AS tissue lysates are shown.
Representative staining and protein analysis
are shown from five independent
experiments. *P < .05, significantly different as
indicated; ns, not significant
SIKURA ET AL. 9BJP3.6 | Expression of CSE and generation of H2SH2S
in human aortic valves
CSE is one of the main endogenous hydrogen sulfide producing pro-
teins in the human body. Using western blot analyses, we investigated
the expression of CSE in tissue lysates of human AS and AI valves. We
found higher expression of CSE in AS valves with massive calcification,
compared with the expression in AI valves known to lack calcification
(Figure 7a). In contrast, sulfide levels that can be precipitated by Zn2+
under alkaline conditions from tissue lysates of valves were markedly
and significantly lower in calcified AS specimens compared to not cal-
cified AI specimens (Figure 7b). Next, we performed dual immunohis-
tochemistry analyses (CSE‐SMA and CSE‐ALP) on human AI and AS
valves to localize CSE. As shown in Figure 7, less SMA+ and more
CSE+ cells were present in calcified AS tissue than in AI tissue (upper
panels). ALP‐CSE double staining revealed the appearance of ALP+
cells expressing high levels of CSE protein in AS valve samples, while
ALP+ cells were not detected in AI valve (Figure 7c; lower panels).The potential of osteoblastic differentiation was dependent upon
the origin of VIC. Under the same calcifying conditions, VIC derived
from AS exhibited earlier mineralization than AI. The higher CSE level
found in AI was accompanied by delayed calcification (Figure 7c).
Human CSE recombinant protein was used as a control for the CSE
western blot (Figure S8B).3.7 | H2S prevents valvular calcification in
apolipoprotein E deficient mice
As demonstrated by von Kossa staining (Figure 8; middle panels),
calcific nodules appeared in aortic heart valves of ApoE−/− mice, on a
high‐fat diet (second column; middle panel) as opposed to ApoE−/−
mice on standard chow diet, where no valvular calcification was
observed (first column; middle panel). ApoE−/− mice on a high‐fat diet
exhibited an expansion of extracellular matrix in aortic valve tissue,
compared to samples from those that received standard diet (upper
FIGURE 4 AP72 enhances generation of
PPi. VIC were cultured in growth medium or
calcification medium alone or supplemented
with AP72 (20 μmol·L−1) for 5 days.
Differences in (a) ENPP2 protein and mRNA
levels, (b) ANK1 protein and mRNA levels, (c)
pyrophosphate level measured using a
PPiLight pyrophosphate detection kit are
presented. (d) Representative ENPP2 western
blot from AI and AS tissue lysate of heart
valves. (e) Pyrophosphate levels of heart valve
tissues were measured using a pyrophosphate
detection kit. Data shown are means ± SEM of
five independent experiments. *P < .05,
significantly different as indicated; ns, not
significant
10 SIKURA ET AL.BJPpanels). To demonstrate the benefit of H2S in vivo, we administered
AP72 intraperitoneally (266‐μmol·kg−1 body weight) and assessed val-
vular calcification in ApoE−/− mice on a high‐fat diet. AP72 signifi-
cantly inhibited the development of calcific nodules in aortic valves
(third column; middle panels) and decreased the expansion of extracel-
lular matrix (third column; upper panels). As observed in samples from
human aortic stenosis, the amount of CSE+ cells in the calcified aortic
valves of mice fed with the high‐fat diet was increased as compared to
the aortic valves of mice on a regular diet (lower panels). Conse-
quently, the administration of exogenous H2S lowered the total mea-
sured expression of CSE in aortic valves of mice fed with a high‐fat
diet (third column; lower panels). α‐SMA staining demonstrated that
AP72 maintained the phenotype of VIC in the aortic valve (Figure 8).4 | DISCUSSION
CAVD is the most common valvular heart disease, found mostly in
patients with CKD and in the elderly (Freeman & Otto, 2005). With
increasing life expectancy, the prevalence of CAVD is expected to rise
(Freeman & Otto, 2005; Mohler, Adam, McClelland, Graham, &Hathaway, 1997; O'Brien et al., 1995). More recently it has been pro-
posed that therapies targeting the molecular processes of aortic valve
calcification (Yutzey et al., 2014) could increase the durability of surgi-
cally implanted and transcatheter bioprosthetic valves (Leopold, 2012).
Increased phosphate levels are a significant risk factor for CAVD
and have been demonstrated in many studies to act as a key regulator
of vascular calcification (Adeney et al., 2009; Giachelli, 2009; Hruska,
Mathew, Lund, Qiu, & Pratt, 2008). It provokes calcification of vascu-
lar cells in a process mediated by sodium‐dependent phosphate co‐
transporters (Pit1 and Pit2) which facilitate the entry of phosphate
into the cells (Zarjou et al., 2009). This induces osteoblastic transition
of vascular smooth muscle cells via a process that is accompanied by
translocation of RUNX2 from the cytosol into the nucleus required
for osteoblast differentiation, bone matrix gene expression, and, con-
sequently, bone mineralization (Komori, 2006; Zarjou et al., 2009).
There is also induction of ALP, an important enzyme in early osteo-
genesis and of osteocalcin, a major non‐collagenous protein found in
bone matrix that is demonstrated to regulate mineralization (Zarjou
et al., 2009).
We have earlier demonstrated that CSE expression was elevated in
human atheroma, derived from the carotid artery, with lipid
FIGURE 5 Simultaneous silencing or
pharmacological inhibition of CSE and CBS
increases calcification of VIC. VIC were
cultured in growth medium or calcification
medium. Cystathionine‐γ‐lyase (CSE) and
CSE/CBS (cystathionine‐β‐synthase) double
gene silencing using siRNA was performed. (a)
Calcium content, (b) CSE and CBS levels of
VIC after silencing of CSE are shown. Panel (c)
shows the calcium content of CSE/CBS
double silenced samples. Panel (d) shows the
calcium contents of pharmacological inhibition
of CSE and CBS. (e) Calcium depositions of
CSE/CBS double silenced VIC were shown.
Data shown are means ± SEM of five
independent experiments. *P < .05,
significantly different as indicated; ns, not
significant
SIKURA ET AL. 11BJPaccumulation without calcification (Potor et al., 2018). In the present
study, we found that CSE expression was higher in human AS valves
known to be associated with calcification, compared with that in AI
valves lacking calcification (Figure 5a). Furthermore, ALP+ cells were
shown to exhibit CSE positivity (Figure 7a) in AS valves. Importantly,
the generation of H2S was decreased in AS heart valve tissue
(Figure 7b) compared with that in AI valves, suggesting that loss of
CSE activity and/or H2S bioavailability might aggravate the progres-
sion of mineralization of VIC. To investigate whether endogenous
H2S production had an anti‐calcification effect, we silenced CSE in
VIC isolated from human aortic valves without calcification then
cultured the cells in high phosphate containing medium. Based on
the observed protecting roles of sulfide administration, we expected
that CSE silencing would enhance VIC calcification. In contrast, therewas no increase in the calcium deposition after silencing CSE expres-
sion (Figure 5a). The interaction between CSE/CBS expression was
reported by Nandi and Mishra (2017), demonstrating that CBS defi-
ciency up‐regulates CSE protein levels. Therefore, we investigated
the expression of CBS in CSE silenced VIC and found that CSE silenc-
ing resulted in an increased CBS protein expression in VIC (Figure 5b).
We therefore silenced both CSE and CBS, which further increased
calcium accumulation in the extracellular matrix of VIC cultured in high
phosphate containing medium (Figure 5c). Furthermore, when we
followed the progression of calcification, we found that CSE+CBS
silenced VIC underwent calcification earlier compared to cells main-
tained in calcification medium without siRNA (Figure 5e). Treatment
of VIC with a synthetic CSE inhibitor (PPG) together with a CBS
inhibitor (AOAA) also enhanced the extracellular calcium deposition
FIGURE 6 Hydrogen sulfide donors leads to inhibition of phosphate transport. Cells were cultured in a normal or calcific environment exposed
to AP72 (20 μmol·L−1) for 5 days. (a) Phosphate content was determined using QuantiChrom quantitative colorimetric assay. (b) Pit1 and (c) Pit2
western blotting was performed and normalized to GAPDH. Data shown are means ± SEM of five independent experiments. *P < .05, significantly
different as indicated; ns, not significant
12 SIKURA ET AL.BJP(Figure 5d). The protective function of CSE was also supported by the
finding that lower expression of CSE found in AS, compared with AI,
was associated with higher calcification rate of VIC (Figure 7c). These
results are consistent with the notion that there is impaired H2S
bioavailability and/or defective endogenous H2S production in CAVD.
Hence, strategies which overcome this loss of H2S, such as H2S donor
compounds, represent a novel strategy for preventing, delaying,
and/or reversing mineralization of VIC in CAVD susceptible
individuals. However, it has to be noted that CSE and CBS are
transsulfuration enzymes working in concert with cysteine production
from homocysteine, via their canonical activities. The metabolic path-
ways of cysteine (also including the oxidative catabolism as well as the
reverse transsulfuration pathways, which can produce H2S) are highly
orchestrated and fine‐tuned to—among other reasons—keep steady‐
state cysteine levels in a narrow concentration range. The homeostatic
effects of sulfite and hydrogen sulfide are critical for cysteine catabo-
lism. Therefore, the CSE/CBS double knockdown cell line is expected
to not only produce less endogenous H2S but also exhibit impaired
cysteine formation. The relative contributions of these processes need
further investigations.To gain insight into the contribution of endogenous sulfide produc-
tion to prevent mineralization of VIC, we employed several H2S gener-
ating molecules. For example, we used NaSH and Na2S which instantly
generate H2S in aqueous solution as well as the slow sulfide release
donor molecules (GYY4137, AP67, and AP72). It is important to note
that the concentrations of donors do not represent the total amount
of released sulfide, and all slow donors have different sulfide‐releasing
potential. In addition, it is increasingly recognized that slow‐releasing
H2S donors are likely to more closely mimic the effects of the endog-
enous H2S buffer system, because of their slow generation of low
sulfide levels (Nagy et al., 2014; Whiteman et al., 2015). In particular,
we have shown that slow‐releasing H2S molecules such as AP72
(Nagy et al., 2014) exhibited a greater inhibition of the calcification,
compared with GYY4137, possibly because the rate of H2S release
from AP72 is faster than that of GYY4137, a poorly efficient H2S
donor (Whiteman et al., 2015). It is important to note that phenols
are capable of absorbing a high amount of H2S from liquids (Huang
et al., 2017). Accordingly, in our experiments, AP72 inhibited VIC
mineralization at one‐order magnitude lower concentration in phenol
red‐free media. Additionally, phosphate uptake of the cells was
FIGURE 7 Expression of CSE in human aortic valves. (a) Western blot of CSE protein from AS valve (N = 12) lysates and AI valve (N = 9) lysates
(left panel) were performed. Representative CSE protein levels of three AS and three AI valves lysates were shown. Relative CSE levels were
assessed by densitometry analyses of band intensities of CSE western blots normalized to GAPDH (panel right). (b) Zn2+ precipitated sulfide
content under alkaline conditions was measured in AI (N = 18) and AS (N = 18) valve tissues normalized to protein content of the individual
samples. (c) VIC derived from different AI (N = 6) and AS (N = 9) patients were cultured in calcification medium. CSE expression was measured
after the initiation of calcification. Results were normalized to GAPDH of the samples. (d) Double immunohistochemistry of CSE‐SMA and CSE‐
ALP was shown with two different magnifications (×400 magnification and ×1,000 magnification). Data shown are means ± SEM of N
experiments. *P < .05, significantly different as indicated
SIKURA ET AL. 13BJPelevated in the process of calcification followed by nuclear transloca-
tion of the RUNX2 from the cytoplasm to the nucleus. Recently, Sun
et al. previously demonstrated the importance of RUNX2 in bone
and in arterial calcification. They showed that RUNX2 was important
in regulating the expression of many factors, including RANKL, which
is the key protein in the interplay between venous smooth muscle
cells and macrophages and contributes to the pathogenesis of vascular
calcification and atherosclerosis (Lin, Chen, Leaf, Speer, & Giachelli,
2015; Sun et al., 2012). Inhibiting phosphate uptake (Figure 6a)—most
likely by post‐translational modification of Pit channels—H2S attenu-
ated RUNX2 translocation and thereby prevents the appearance of
the osteoblastic phenotype (Figure 3), as reflected by ALP, osteocalcinprotein expression, and the development of the hydroxyapatite
crystals (Figure 2).
Plasma PPi acts as an endogenous inhibitor of vascular calcifica-
tion, and levels of PPi are reduced in end‐stage renal disease and
inversely correlate with arterial calcification (Lomashvili, Narisawa,
Millan, & O'Neill, 2014). We therefore asked whether H2S could affect
the regulation of PPi generation, an observation that could provide a
new pathway to inhibit VIC calcification in CAVD. Indeed, in human
calcified valves of AS, ENPP2 protein and PPi levels were lower
compared to AI valve tissue (Figure 4a,c,d), and we demonstrated that
the expression of ENPP2 is markedly up‐regulated by AP72 (Figure 4a)
resulting in an increased production of PPi in VIC (Figure 4c).
FIGURE 8 Hydrogen sulfide inhibits valvular calcification in ApoE−/− knockout mice. Haematoxylin and eosin (upper panels), von Kossa (middle
panels), CSE (second middle panels), and α smooth muscle actin (α‐SMA; lower panels) staining was performed on aortic valves of mice fed a
normal diet (first column; N = 5), on a high‐fat diet (second column, N = 9); and on a high‐fat diet treated with AP72 (third column; N = 5).
Comparison (>) designates the calcified regions, and arrow indicates CSE positive cells
14 SIKURA ET AL.BJPFurthermore, AP72 treatment increased the expression of ANK1
channels which contributed to the extracellular localization of PPi
from the cytoplasm (Figure 4b). Taken together, the regulation of
PPI generation by H2S represents a novel additional mechanism to
control calcification.
The ApoE−/− mouse is the most widely studied animal model for
atherosclerosis (Massy et al., 2005; Rattazzi et al., 2005). We showed
that calcification occurred in the aorta and aortic valves after a high‐
fat diet with the most pronounced calcification seen in the aortic arch.
In our current study, the development of mineralization in aortic
valves of ApoE−/− mice on a high‐fat diet was strongly associated with
the increase of extracellular matrix and the formation of hydroxyapa-
tite nodules, and the expansion of extracellular matrix in the heart
valves was prevented by AP72. We also observed that similar to
human aortic stenosis, the expression of CSE in VIC was increased in
mice on a high‐fat diet. Several triggers were previously identified by
our group for inducing CSE expression in resident cells of atheroscle-
rotic lesions including plaque lipids, oxidized LDL, TNF‐α, and IL‐1β
(Potor et al., 2018). Therefore, the induction of CSE might represent
an adaptive cellular response to lipid deposition and inflammation,
serving as a clinical biomarker of CAVD. In the process of the calcifica-
tion, vascular smooth muscle cells were shown to transform intoosteoblastic‐like cells and lose their SMA (Johnson, Leopold, &
Loscalzo, 2006). In our experiments, immunostaining of the aortic
valves of ApoE−/− mice demonstrated that AP72 treatment preserved
α‐SMA (Figure 7, lower panels). In keeping with our hypothesis that
CAVD is a condition of perturbed H2S bioavailability, we found a
deficiency in the generation of H2S in human AS valves in spite of
the elevated expression of CSE. This contradiction can be resolved
by the observations of Bibli et al., (2019), who found a markedly
decreased H2S production after phosphorylation of Ser
377 of CSE,
resulting in enzyme inactivation. As such, therapeutic supplementation
of H2S using H2S donor molecules such as AP72 or other novel com-
pounds that are currently under preclinical or clinical investigation by
us and others may offer a novel approach to prevent valvular calcifica-
tion in CAVD and related conditions.
The pKa values of protein cysteines and their nucleophilicities are
mainly dependent on charged states, orientations, inductive effects
of neighbouring functional groups, and solvent accessibility of the
thiol group (Nagy, 2013). Unfortunately, the accurate crystal struc-
tures of Pit1 and RUNX2 are still not known, which makes it virtually
impossible to appropriately predict reactive cysteine residues on these
proteins, which might be persulfidated with a functional effect on their
activities. However, persulfidation of RUNX2 on Cys123 and Cys132 by
SIKURA ET AL. 15BJPCSE‐produced endogenous sulfide enhanced its transactivation
(Zheng et al., 2017). This effect is in contrast to our observations that
endogenously produced or exogenously administered sulfide inhibited
nuclear translocation of RUNX2, suggesting that the anti‐calcification
effects of H2S are more likely due to the inhibition of phosphate
uptake, and the inhibition of RUNX2 translocation in our model is
likely to be a secondary effect of this, as we proposed above.
In our study, we identify three separate mechanisms for the anti‐
calcification effects of H2S (a) inhibiting phosphate uptake, (b)
preventing nuclear translocation of RUNX2, and (c) increasing pyro-
phosphate level. Although all these pathways are important and
related to each other, some caveats are acknowledged. AP72 exhibits
slight but significant anti‐calcification action at 200 μmol·L−1, although
it did not affect nuclear translocation of RUNX2 indicating the impor-
tance of pyrophosphate for preventing the formation of mineralized
nodules in extracellular matrix.
In conclusion, our study has provided evidence that endogenous
H2S limits calcification of VIC. Pharmacologically generated H2S,
derived from novel H2S‐releasing molecules, may have the potential
to control calcification in heart valves and osteoblastic differentiation
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